DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock News
NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR
DBVT Latest News and Analysis
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF Regulated InformationChâtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies...
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Informations RéglementéesChâtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies...
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.
Wall Street Poised To Open Lower A Day After Nasdaq's Record Close Above 20,000: Expert Flags 'Deterioration Under The Surface' As 117 S&P 500 Stocks Hit New Monthly Lows
U.S. stock futures declined on Thursday in premarket hours after hitting fresh highs on Wednesday. S&P 500, Dow, Nasdaq 100 & R2K were down.
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 –...
DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans
Châtillon, France, le 11 décembre (22 :05 CEST) 2024 DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch...
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024
Information relative au nombre total des droits de vote et d’actions composant le capital...
DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN:...
DBV Technologies annonce son intention de modifier le ratio d'ADS
Châtillon, France, le 11 novembre (22 :30 CET) 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV –...
DBV Technologies Reports Third Quarter 2024 Financial Results
DBV Technologies Reports Third Quarter 2024 Financial Results
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4...
DBV Technologies publie ses résultats financiers du troisième trimestre 2024
Châtillon, France, le 6 novembre (22 :30 CET) 2024 DBV Technologies publie ses résultats financiers du troisième trimestre 2024 DBV clôture le...
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to...
DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en Europe
Châtillon, France, le 22 octobre (22 :15 CEST) 2024 DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en...
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN:...
DBV Technologies participera au prochain congrès de l'ACAAI 2024
Châtillon, France, le 18 octobre (22 :30 CEST) 2024 DBV Technologies participera au prochain congrès de l'ACAAI 2024 DBV Technologies (Euronext...
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024 (Article 223-16 du Règlement Général...
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its...
DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE
Châtillon, France, le 23 septembre 2024 (22 :30 CEST) DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE DBV a...